Parameter
| Biomarker | IL-6 | Full name | Interleukin-6 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction |
| Disease | PCOS | Disease Subtypes | / | ||
| Organ | Ovary | Test Sample / Technology Platform | Serum (ELISA, CLIA, Flow Cytometry CBA) | ||
| Pathobiological Mechanisms | Secreted by adipocytes and immune cells, in PCOS, it promotes liver synthesis of CRP by activating the JAK-STAT pathway, while inhibiting insulin signal transduction, thereby aggravating insulin resistance and ovarian dysfunction. | ||||
| Clinical Availability Status | Research validation stage: Core indicators of the inflammatory mechanism are gradually being applied to clinical risk assessment. | ||||
| Notes and Dynamics | The level of IL-6 is positively correlated with the ovulation frequency, BMI and triglyceride levels of patients with PCOS. Drugs that target and inhibit the IL-6 pathway (such as tocilizumab) have shown potential in improving insulin resistance in small clinical trials. | ||||